دورية أكاديمية
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
| العنوان: | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. |
|---|---|
| المؤلفون: | Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M, Colin-Jones, Rachel, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie J, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Heath, Paul T, Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne HC, Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina CD, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M, Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J, Mallory, Raburn, Mendes, Ana VA, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F, Nana, Anusha, O'Reilly, Peter J, Padayachee, Sherman D, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Rhead, Sarah, Schwarzbold, Alexandre V, Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Tarrant, Richard, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Watson, Marion EE, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, Oxford COVID Vaccine Trial Group |
| بيانات النشر: | Elsevier BV //dx.doi.org/10.1016/s0140-6736(20)32661-1 Lancet |
| سنة النشر: | 2021 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Adolescent, Adult, Aged, Brazil, COVID-19, COVID-19 Vaccines, ChAdOx1 nCoV-19, Double-Blind Method, Female, Humans, Male, Middle Aged, Single-Blind Method, South Africa, Treatment Outcome, United Kingdom, Young Adult |
| الوصف: | BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print-Electronic; application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/315560Test |
| DOI: | 10.17863/CAM.62666 |
| الإتاحة: | https://doi.org/10.17863/CAM.62666Test https://www.repository.cam.ac.uk/handle/1810/315560Test |
| حقوق: | Attribution-NonCommercial-NoDerivatives 4.0 International ; https://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.81160586 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.62666 |
|---|